BACKGROUND: The disease burden of the 2009 influenza pandemic has been debated but reliable estimates are lacking. To guide future policy and control, these estimates are necessary. This study uses burden of disease measurements to assess the contribution of the pandemic influenza A(H1N1) virus to the overall burden of disease in the Netherlands. METHODS: The burden of disease caused by 2009 pandemic influenza was estimated by calculating Disability Adjusted Life Years (DALY), a composite measure that combines incidence, sequelae and mortality associated with a disease, taking duration and severity into account. Available influenza surveillance data sources (primary care sentinel surveillance, notification data on hospitalizations and deaths and death registries) were used. Besides a baseline scenario, five alternative scenarios were used to assess effects of changing values of input parameters. RESULTS: The baseline scenario showed a loss of 5800 DALY for the Netherlands (35 DALY per 100 000 population). This corresponds to 0.13% of the estimated annual disease burden in the Netherlands and is comparable to the estimated disease burden of seasonal influenza, despite a different age distribution in incidence and mortality of the pandemic compared to seasonal influenza. CONCLUSIONS: This disease burden estimate confirmed that, although there was a higher mortality observed among young people, the 2009 pandemic was overall a mild influenza epidemic. The disease burden of this pandemic was comparable to the burden of seasonal influenza in the Netherlands.
BACKGROUND: The disease burden of the 2009 influenza pandemic has been debated but reliable estimates are lacking. To guide future policy and control, these estimates are necessary. This study uses burden of disease measurements to assess the contribution of the pandemic influenza A(H1N1) virus to the overall burden of disease in the Netherlands. METHODS: The burden of disease caused by 2009 pandemic influenza was estimated by calculating Disability Adjusted Life Years (DALY), a composite measure that combines incidence, sequelae and mortality associated with a disease, taking duration and severity into account. Available influenza surveillance data sources (primary care sentinel surveillance, notification data on hospitalizations and deaths and death registries) were used. Besides a baseline scenario, five alternative scenarios were used to assess effects of changing values of input parameters. RESULTS: The baseline scenario showed a loss of 5800 DALY for the Netherlands (35 DALY per 100 000 population). This corresponds to 0.13% of the estimated annual disease burden in the Netherlands and is comparable to the estimated disease burden of seasonal influenza, despite a different age distribution in incidence and mortality of the pandemic compared to seasonal influenza. CONCLUSIONS: This disease burden estimate confirmed that, although there was a higher mortality observed among young people, the 2009 pandemic was overall a mild influenza epidemic. The disease burden of this pandemic was comparable to the burden of seasonal influenza in the Netherlands.
Authors: Rianne A B van Gageldonk-Lafeber; Rob M Riesmeijer; Ingrid H M Friesema; Adam Meijer; Leslie D Isken; Aura Timen; Marianne A B van der Sande Journal: BMC Public Health Date: 2011-10-04 Impact factor: 3.295
Authors: Cees C van den Wijngaard; Liselotte van Asten; Marion P G Koopmans; Wilfrid van Pelt; Nico J D Nagelkerke; Cornelia C H Wielders; Alies van Lier; Wim van der Hoek; Adam Meijer; Gé A Donker; Frederika Dijkstra; Carel Harmsen; Marianne A B van der Sande; Mirjam Kretzschmar Journal: PLoS One Date: 2012-02-03 Impact factor: 3.240
Authors: Anna M M van Deursen; Suzan P van Mens; Elisabeth A M Sanders; Bart J M Vlaminckx; Hester E de Melker; Leo M Schouls; Sabine C de Greeff; Arie van der Ende Journal: Emerg Infect Dis Date: 2012-11 Impact factor: 6.883
Authors: Mariëtte Hooiveld; Tine van de Groep; Theo J M Verheij; Marianne A B van der Sande; Robert A Verheij; Margot A J B Tacken; Gerrit A van Essen Journal: BMC Pharmacol Toxicol Date: 2013-10-21 Impact factor: 2.483